olivLaw · US equity research
Veeva Systems Inc. VEEV
Services-Prepackaged Software · SIC 7372 · Vertical: Services-Prepackaged Software (SIC 7372)
Veeva Systems is a cloud software provider for the life sciences industry, with total revenues of 3195.3 million USD in fiscal 2026. In the second quarter of fiscal 2027, revenues grew 18%. Company guidance for fiscal 2027 points to revenues of 3682-3687 million USD.
At the close of 04 Nov 2026, Veeva Systems Inc. (VEEV) stock was 310.63 USD (+2.45% on the day), with market capitalisation 50.3 bn USD, P/E 50.8 on diluted EPS of 6.12 USD over the last 12 months, beta 0.67, 52-week range 151.43–323.04 USD. Latest reported quarter (Q2 2027): revenue of 928.0 m USD (+17.6% YoY), net income of 273.4 m USD (+36.5% YoY), diluted EPS 1.66 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 57.3
- strong (55–70)
- Bollinger (20, 2)
- 289.58 – 329.86
- in the upper half of the band · %B 0.52 · band width 13.0%
- SMA 50 / 200
- 287.41 / 210.54
- uptrend (price > SMA50 > SMA200)
- MACD (12, 26, 9)
- 7.74 / 10.42
- MACD below signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | +9.6% | −1.1% | +10.7 pp | — |
| 3 months | +45.5% | −0.5% | +45.9 pp | — |
| 6 months | +85.6% | +4.4% | +81.2 pp | — |
| Year to date | +39.2% | +12.3% | +26.8 pp | — |
| 1 year | +5.8% | +13.5% | −7.7 pp | −1.3% |
| 3 years | +59.6% | +76.4% | −16.8 pp | +23.8% |
| 5 years | −2.6% | +63.7% | −66.2 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q2 2027 · 31 Jul 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 | Q4 '26 | Q1 '27 | Q2 '27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 699.2 m | 720.9 m | 759.0 m | 789.1 m | 811.2 m | 836.0 m | 882.9 m | 928.0 m |
| Cost of revenue | 174.4 m | 181.0 m | 173.8 m | 195.3 m | 199.5 m | 213.5 m | 220.9 m | 232.0 m |
| Gross profit | 524.8 m | 539.9 m | 585.2 m | 593.8 m | 611.8 m | 622.5 m | 662.0 m | 696.0 m |
| Research & development | 172.4 m | 181.5 m | 184.0 m | 192.7 m | 191.9 m | 198.8 m | 208.3 m | 222.9 m |
| Operating income | 181.4 m | 188.4 m | 233.7 m | 195.9 m | 240.9 m | 245.9 m | 273.1 m | 275.0 m |
| Pre-tax income | 242.3 m | 245.1 m | 298.8 m | 265.4 m | 312.8 m | 317.5 m | 347.5 m | 349.5 m |
| Income tax | 56.5 m | 49.5 m | 70.6 m | 65.1 m | 76.6 m | 73.3 m | 86.6 m | 76.1 m |
| Net income | 185.8 m | 195.6 m | 228.2 m | 200.3 m | 236.2 m | 244.2 m | 260.9 m | 273.4 m |
| Diluted EPS | 1.13 | 1.18 ≈ | 1.37 | 1.19 | 1.40 | 1.49 ≈ | 1.57 | 1.66 |
| Operating cash flow | 164.1 m ≈ | 69.5 m | 877.2 m | 238.4 m ≈ | 192.8 m ≈ | 106.8 m | 1.1 bn | 238.7 m ≈ |
| Share repurchases | — | — | 0 | 0 ≈ | — | — | 226.9 m | 245.7 m ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Today's P/E sits at the 9 percentile of its own 43-quarter history (min 27.6, median 71.4, max 128.4; quarters with earnings only).
Fiscal years
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 862.2 m | 1.1 bn | 1.5 bn | 1.9 bn | 2.2 bn | 2.4 bn | 2.7 bn | 3.2 bn |
| Revenue YoY | +24.9% | +28.1% | +32.7% | +26.3% | +16.4% | +9.7% | +16.2% | +16.3% |
| Net income | 229.8 m | 301.1 m | 380.0 m | 427.4 m | 487.7 m | 525.7 m | 714.1 m | 908.9 m |
| Net income YoY | +52.0% | +31.0% | +26.2% | +12.5% | +14.1% | +7.8% | +35.8% | +27.3% |
| Diluted EPS | 1.47 | 1.90 | 2.36 | 2.63 | 3.00 | 3.22 | 4.32 | 5.44 |
| Diluted EPS YoY | +50.0% | +29.3% | +24.2% | +11.4% | +14.1% | +7.3% | +34.2% | +25.9% |
| net % | 26.7% | 27.3% | 25.9% | 23.1% | 22.6% | 22.2% | 26.0% | 28.4% |
| Free cash flow | 302.4 m | 434.3 m | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2026 · 31 Jan 2026
- Cash
- 1.4 bn USD
- Financial debt
- unavailable USD
- Net debt
- unavailable USD
- Equity
- 7.2 bn USD
- Total assets
- 9.0 bn USD
- Debt / equity
- unavailable
- Current ratio
- 4.89x
- ROE
- 13.9%
- ROA
- 11.1%
- FCF margin
- unavailable
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 1.5 bn | 1.9 bn | 2.2 bn | 2.4 bn | 2.7 bn | 3.2 bn | SEC (XBRL)· 20 Mar 2026verified |
| Cost of revenue | 408.9 m | 503.7 m | 609.4 m | 677.3 m | 699.6 m | 782.0 m | SEC (XBRL)· 20 Mar 2026verified |
| Gross profit | 1.1 bn | 1.3 bn | 1.5 bn | 1.7 bn | 2.0 bn | 2.4 bn | SEC (XBRL)· 20 Mar 2026verified |
| Research & development | 294.2 m | 382.0 m | 520.3 m | 629.0 m | 693.1 m | 767.4 m | SEC (XBRL)· 20 Mar 2026verified |
| Operating income | 377.8 m | 505.5 m | 459.1 m | 429.3 m | 691.4 m | 916.4 m | SEC (XBRL)· 20 Mar 2026verified |
| Pre-tax income | 394.0 m | 512.3 m | 509.1 m | 588.0 m | 919.4 m | 1.2 bn | SEC (XBRL)· 20 Mar 2026verified |
| Income tax | 14.0 m | 84.9 m | 21.4 m | 62.3 m | 205.2 m | 285.6 m | SEC (XBRL)· 20 Mar 2026verified |
| Net income | 380.0 m | 427.4 m | 487.7 m | 525.7 m | 714.1 m | 908.9 m | SEC (XBRL)· 20 Mar 2026verified |
| Diluted EPS | 2.36 | 2.63 | 3.00 | 3.22 | 4.32 | 5.44 | SEC (XBRL)· 20 Mar 2026verified |
| Weighted average diluted shares | 160.7 m | 162.3 m | 162.4 m | 163.5 m | 165.2 m | 167.0 m | SEC (XBRL)· 20 Mar 2026verified |
Balance sheet · USD
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 730.5 m | 1.1 bn | 886.5 m | 703.5 m | 1.1 bn | 1.4 bn | SEC (XBRL)· 20 Mar 2026verified |
| Receivables | 564.4 m | 631.1 m | 703.1 m | 852.2 m | 1.0 bn | 1.3 bn | SEC (XBRL)· 20 Mar 2026verified |
| Current assets | 2.3 bn | 3.1 bn | 4.0 bn | 5.0 bn | 6.3 bn | 8.0 bn | SEC (XBRL)· 20 Mar 2026verified |
| Property, plant & equipment, net | 53.7 m | 54.5 m | 49.8 m | 58.5 m | 55.9 m | 70.3 m | SEC (XBRL)· 20 Mar 2026verified |
| Goodwill | 436.0 m | 439.9 m | 439.9 m | 439.9 m | 439.9 m | 439.9 m | SEC (XBRL)· 20 Mar 2026verified |
| Intangibles (excl. goodwill) | 114.6 m | 101.9 m | 82.5 m | 63.0 m | 44.5 m | 30.3 m | SEC (XBRL)· 20 Mar 2026verified |
| Total assets | 3.0 bn | 3.8 bn | 4.8 bn | 5.9 bn | 7.3 bn | 9.0 bn | SEC (XBRL)· 20 Mar 2026verified |
| Accounts payable | 23.3 m | 20.3 m | 41.7 m | 31.5 m | 30.4 m | 37.6 m | SEC (XBRL)· 20 Mar 2026verified |
| Current liabilities | 716.0 m | 840.8 m | 1.0 bn | 1.2 bn | 1.4 bn | 1.6 bn | SEC (XBRL)· 20 Mar 2026verified |
| Total liabilities | 779.7 m | 904.8 m | 1.1 bn | 1.3 bn | 1.5 bn | 1.8 bn | SEC (XBRL)· 20 Mar 2026verified |
| Equity | 2.3 bn † | 2.9 bn † | 3.7 bn † | 4.6 bn † | 5.8 bn † | 7.2 bn † | SEC (XBRL)· 20 Mar 2026verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | 551.2 m | 764.5 m | 780.5 m | 911.3 m | 1.1 bn | 1.4 bn | SEC (XBRL)· 20 Mar 2026verified |
| Investing cash flow | -333.6 m | -346.2 m | -1.0 bn | -1.1 bn | -700.1 m | -1.1 bn | SEC (XBRL)· 20 Mar 2026verified |
| Financing cash flow | 33.8 m | -4.1 m | -19.4 m | -16.2 m | 26.1 m | -9.3 m | SEC (XBRL)· 20 Mar 2026verified |
| Share repurchases | — | — | — | 0 | 0 | 169.9 m | SEC (XBRL)· 20 Mar 2026verified |
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
4 indicators that do not apply to the sector.
Valuation
olivLaw classification
- score weight coverage: 55.3% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 50.3 bn USD
Key indicators
Coverage and freshness
Score by group
55% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · the input exists, but its latest figure is far older than the latest reported period: not used
- Peers: EV/Salesunavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: EV/EBITDAunavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
no valuation method could be computed
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: score weight coverage: 55.3% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| Gross margin · Quality | 75.0% | 87 (on a fixed band) | 19% |
| EBIT margin · Quality | 29.9% | 86 (vs peers) | 15% |
| FCF margin · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | 14.0% | 56 (on a fixed band) | 31% |
| Revenue growth (YoY) · Growth | 16.3% | 50 (vs peers) | 15% |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Current ratio · Balance sheet | 5.5x | 100 (on a fixed band) | 12% |
| EV/Sales · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | unavailable | unavailable | — |
| Shareholder yield (distributions) · Returns | 1.3% | 55 (on a fixed band) | 8% |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet· partial100/100 · 1/2 factors with a value
- Growth54/100 · 2/2 factors with a value
- Quality87/100 · 2/3 factors with a value
- Returns55/100 · 1/1 factors with a value
- Valuation· partialunavailable · 0/2 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
Veeva Systems Inc. (VEEV). Latest full fiscal year: 2026; data up to 2026-07-31.
Figures computed from the financial statements: revenue 3.2 bn USD in 2026; YoY growth 16.3%; net margin 29.3%; ROE 14.4%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (score weight coverage: 55.3% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Gross margin: 75.0%
- EBIT margin: 29.9%
- Current ratio: 5.5x
What contradicts it
No signal among the computed factors. That is not an absence of risk: factors without data were not assessed, and business risks (margins, inventory, demand) are in the source-based analysis.
Not assessed (insufficient data or a ratio without meaning): FCF margin, Net debt / EBITDA, EV/Sales, FCF yield.
Versus the vertical median
Services-Prepackaged Software (SIC 7372) · same industry (4-digit SIC) · compared with 22 companies
Only companies with a capitalisation between 6.5 bn and 417.8 bn (within 8× of the company's); 199 of the vertical were left out.
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| ORCLOracle Corporation | 374.1 bn | 19.3 | 41.6% | 26.4% | +17.3% | −39% / +6% |
| CRWDCrowdStrike Holdings, Inc. | 246.8 bn | 1,120.4 | 1.3% | 1.1% | +21.7% | +89% / +307% |
| CRMSalesforce, Inc. | 186.9 bn | 20.7 | 19.4% | 22.0% | +9.6% | −1% / −10% |
| NOWServicenow, Inc. | 112.9 bn | 78.1 | 11.8% | 9.4% | +20.9% | −33% / −21% |
| SNOWSnowflake Inc. | 102.5 bn | — | -48.2% | -20.1% | +29.2% | +16% / +55% |
| ADBEAdobe Inc. | 96.7 bn | 13.9 | 61.9% | 28.0% | +10.5% | −22% / −59% |
| INTUIntuit Inc. | 95.3 bn | 21.7 | 23.6% | 21.3% | +13.9% | −44% / −38% |
| CDNSCadence Design Systems, Inc. | 90.4 bn | 65.5 | 22.9% | 22.5% | +14.1% | +6% / +21% |
| SNPSSynopsys Inc | 88.7 bn | 81.8 | 3.7% | 11.4% | +15.1% | +11% / −15% |
| ADSKAutodesk, Inc. | 56.4 bn | 35.0 | 53.9% | 21.1% | +17.5% | −11% / +24% |
| VEEVVeeva Systems Inc. | 50.3 bn | 50.8 | 14.4% | 29.3% | +16.3% | +6% / +60% |
| TTWOTake-Two Interactive Software, Inc. | 39.1 bn | — | -9.0% | -4.8% | +18.2% | −15% / +32% |
| RBLXRoblox Corporation | 35.3 bn | — | -478.2% | -16.5% | +35.8% | −48% / +25% |
| TWLOTwilio Inc. | 33.0 bn | 26.8 | 14.9% | 21.8% | +13.7% | +65% / +230% |
| MDBMongodb, Inc. | 26.5 bn | 449.1 | 2.0% | 2.1% | +22.8% | −1% / −21% |
| PTCPTC Inc. | 21.2 bn | 19.0 | 35.1% | 41.4% | +19.2% | +11% / +24% |
| UUnity Software Inc. | 18.7 bn | — | -18.9% | -29.0% | +2.0% | −0% / +44% |
| SSNCSs&C Technologies Holdings, Inc. | 18.7 bn | 22.9 | 12.7% | 13.2% | +6.6% | −7% / +41% |
| NTNXNutanix, Inc. | 17.2 bn | 12.3 | 37,460.2% | 52.8% | +12.4% | +33% / +48% |
| TYLTyler Technologies, Inc. | 16.8 bn | 53.3 | 10.5% | 13.5% | +9.1% | −10% / +4% |
| DOCUDocusign, Inc. | 15.0 bn | 49.1 | 17.8% | 9.8% | +8.2% | +16% / +87% |
| GWREGuidewire Software, Inc. | 14.0 bn | 104.7 | 10.5% | 9.4% | +22.7% | −21% / +71% |
| DTDynatrace, Inc. | 13.4 bn | 87.0 | 6.4% | 7.4% | +18.8% | +5% / −13% |
1- and 3-year price returns: for VEEV from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | 206.12 Total return -34% · Per year -34% | 362.89 Total return 17% · Per year 17% | 544.53 Total return 75% · Per year 75% |
| 3 years | 240.20 Total return -23% · Per year -8% | 471.86 Total return 52% · Per year 15% | 771.49 Total return 148% · Per year 35% |
| 5 years | 279.91 Total return -10% · Per year -2% | 613.54 Total return 98% · Per year 15% | 1,093.05 Total return 252% · Per year 29% |
- Exit P/E± 117.96
- Net margin± 82.57
- Annual revenue growth± 62.11
- Annual dilution± 6.94
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
Veeva Systems is a cloud software provider for the life sciences industry, with total revenues of 3195.3 million USD in fiscal 2026 1. In the second quarter of fiscal 2027, revenues grew 18% 3. Company guidance for fiscal 2027 points to revenues of 3682-3687 million USD 3.
SWOT
Strengths
Weaknesses
Opportunities
Risks
- Data securityhigh
A security incident could lead to loss of client trust, litigation and remediation costs that exceed insurance coverage 1.
- Client concentrationmedium
The loss of one of the key clients could significantly reduce revenues 1.
- Vault CRM migrationhigh
If clients do not move successfully to Vault CRM, revenues could decline and client relationships could suffer 1.
- Dependence on life sciences industrymedium
Funding and drug pricing policies could affect client budgets 1.
- Reliance on third-party infrastructurelow
Disruptions at cloud providers could affect the services delivered to clients 1.
Investment thesis
What would need to be true (bull case)
- Revenue growth has remained solid and guidance for fiscal 2027 was raised, which could support continued expansion 3.
- Its leading cloud position in life sciences and large clients could provide predictable recurring revenue 1.
- AI agents could open new product categories and increase the value offered to clients 13.
What to watch
- Third-quarter results and updated guidanceQ3 fiscal 2027
- Progress of the Vault CRM migration and number of live clients2027
- Commercial launch of Veeva Falcon and adoption of AI agents2027
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
Veeva delivers industry cloud solutions for pharmaceutical, biotechnology and medical device companies, grouped into four categories: Veeva Development Cloud, Veeva Quality Cloud, Veeva Commercial Cloud and Veeva Data Cloud 1. The company served 1552 customers as of January 31 2026 1. Veeva is a Delaware public benefit corporation 1.
The revenue model rests on subscriptions, which made up 84% of total revenues in fiscal 2026, with the rest coming from professional and consulting services 1. Subscriptions are recognized ratably over the contract term, and CRM orders generally have a one-year term 1.
The company is extending its Veeva Vault platform with AI agents, including Vault CRM, which gradually replaces the legacy Veeva CRM, and in the second quarter of fiscal 2027 it reported progress on the Veeva Falcon project 13.
Segments
R&D and Quality Solutions
This category includes Veeva Development Cloud and Veeva Quality Cloud and represented 55% of total revenues in fiscal 2026, with a trend toward a larger share 1.
Professional services and consulting
Implementation, configuration and consulting services generate the remaining revenues, at a lower margin than subscriptions because of high labor costs 1.
Market context
The market is global and concentrated among pharmaceutical and biotechnology companies, where large clients and emerging companies buy domain-specific cloud solutions 1. Competition is intense and evolving quickly with new AI technologies 1.
Revenues depend on the spending budgets of the life sciences industry, on public funding policies and on drug pricing regulation, factors that could influence demand 1.
Trends
- Adoption of AI agentstailwind
Veeva is embedding AI agents in its Vault platform and applications; if adoption grows, it could support subscription revenue growth 13.
- Migration from Veeva CRM to Vault CRMmixed
Moving customers to Vault CRM could cause operational disruption and the loss of some clients who choose Salesforce 1.
- Macroeconomic and geopolitical pressureheadwind
Trade tariffs, inflation and geopolitical conflicts could weigh on pharmaceutical client budgets 1.
- Expansion into R&D and qualitytailwind
The share of development and quality products could rise in total revenues, especially if clients adopt the clinical and safety applications 13.
Competitive position
In CRM, the main competitor is Salesforce, which has built an industry-specific CRM and has won large clients moving from Veeva CRM 1. For data and analytics, Veeva competes with IQVIA, Ipsos and Definitive Health 1.
For development and quality applications, competition comes from IQVIA, Dassault Systèmes, OpenText, Oracle and Honeywell, and larger rivals may have greater financial resources and intellectual property portfolios 1.
- SalesforceCRM
Main CRM competitor with an industry-specific application that has won large clients moving from Veeva CRM 1.
- IQVIA
Competitor in data, analytics and some development applications; it previously offered a CRM and licensed that software to Salesforce 1.
- Dassault Systèmes
Competitor for certain development and quality applications in the Veeva portfolio 1.
- OracleORCL
Provider of legacy client-server applications and of applications competing in development and quality 1.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
- Veeva Systems ( VEEV ) – Research Analyst Weekly Ratings UpdatesSurge — GDELT DOC · 20 Oct 2026 · RO
SEC filings
- Quarterly report27 Aug 2026
- Current report26 Aug 2026Results of operations · Financial statements and exhibits
- Current report20 Aug 2026Departure or appointment of officers · Financial statements and exhibits
- Current report18 Jun 2026Shareholder vote · Financial statements and exhibits
- Quarterly report05 Jun 2026
- Current report03 Jun 2026Results of operations · Financial statements and exhibits
- Proxy statement04 May 2026
- Current report20 Apr 2026Departure or appointment of officers · Financial statements and exhibits
- Annual report20 Mar 2026
- Current report04 Mar 2026Results of operations · Financial statements and exhibits
Sources
- [1] Form 10-K, fiscal year ended 2026-01-31 · SEC / Veeva Systems Inc. · 20 Mar 2026
- [2] Form 10-Q, quarter ended 2026-07-31 · SEC / Veeva Systems Inc. · 27 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / Veeva Systems Inc. · 26 Aug 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.